

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings of claims in the application:

LISTING OF CLAIMS:

1.-13. (canceled)

14. (currently amended) A DNA transfer vector containing a comprising a nucleotide sequence coding for a fragment, wherein said sequence is selected from the group consisting of SEQ ID [[N.]] NO: 1, 2, 3, 4, 5, 6, 8, 9, 10, 11, 12, 13, and 14.

15. (currently amended) A The DNA transfer vector according to claim 14, which wherein said vector is a plasmid.

16. (currently amended) The DNA transfer vector of claim 15, further containing comprising a transcription promotor.

17. (currently amended) The DNA transfer vector of claim 16, wherein the transcription promotor is CMV.

18. (currently amended) The DNA transfer vector of claim 15, further containing comprising 4 CpG motifs.

19. (currently amended) The DNA transfer vector of claim 18, further containing comprising 8 CpG motifs.

20. (currently amended) A Pharmaceutical pharmaceutical composition containing comprising a DNA transfer vector according

to claim 14 in admixture with pharmaceutically acceptable vehicles and excipients.

21. (currently amended) The pharmaceutical composition according to claim [[7]] 20, which wherein said composition is in a form for parenteral administration.

22. (currently amended) The pharmaceutical composition of claim [[8]] 21, which wherein said composition is in the form of an injectable solution.

23. (withdrawn and currently amended) A combined pharmaceutical preparation ~~containing~~ comprising at least two different DNA transfer vectors according to claim 14, for simultaneous, sequential or separate therapeutic use.

24. (withdrawn and currently amended) ~~A~~ The combined preparation according to claim 23, which wherein said preparation is in a form suitable for DNA vaccination.

25. (withdrawn and currently amended) A method for the preventive or therapeutical treatment of a subject at risk of developing p185neu positive tumours, or of a subject having primary tumours, metastasis or relapses of p185neu-expressing tumours, comprising administering to said subject an effective amount of a DNA transfer vector according to claim 14.

26. (withdrawn) The use according to claim 25, for the preparation of a DNA vaccine.